Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
Pharmacol Res Perspect. 2021 Apr;9(2):e00733. doi: 10.1002/prp2.733.
Pharmacol Res Perspect. 2021.
PMID: 33682358
Free PMC article.
Clinical Trial.
A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
Zhu X, Qian H, Sun J, Wu M, Yu C, Ding Y, Zhang X, Chai K, Li X.
Zhu X, et al.
Cancer Chemother Pharmacol. 2021 Sep;88(3):465-474. doi: 10.1007/s00280-021-04297-z. Epub 2021 Jun 4.
Cancer Chemother Pharmacol. 2021.
PMID: 34086067
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite